A Phase I Study of Telomelysin Added to Chemoradiation for Patients with Advanced Inoperable Esophageal Cancer

Memorial Sloan Kettering Cancer Center recently began recruiting patients for a phase 1 clinical trial to test a treatment in which an investigational cancer cell-killing virus called Telomelysin is directly injected into inoperable esophageal cancer tumors. Participating patients will receive this “cancer vaccine” alongside standard chemoradiation therapy.